Status:
WITHDRAWN
Enhancing Processing Speed and Executive Functioning in Depressed Older Adults With Computerized Cognitive Training
Lead Sponsor:
Queens College, The City University of New York
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
New York State Psychiatric Institute
Conditions:
Depression in Old Age
Depression
Eligibility:
All Genders
50+ years
Phase:
PHASE1
Brief Summary
The purpose of this research study is to determine how treatment response may change depending on how studies are designed, and if mobile cognitive training can be used to improve treatment response i...
Detailed Description
Major Depressive Disorder (MDD) is a leading cause of disability, morbidity, and mortality across the lifespan and poses a particularly severe public health problem in late life. Late-life depression ...
Eligibility Criteria
Inclusion
- Age greater than or equal to 60 years
- DSM5 Diagnosis of Major Depressive Disorder (MDD), Persistent Depressive Disorder, or Depression Not Otherwise Specified (NOS)
- Hamilton Rating Scale for Depression (HRSD) score ≥ 20
- Decreased processing speed (1 SD below age-adjusted norms on the WAIS-IV Digit Symbol Coding Test)
- Access to a computer with daily internet access
- Willing to and capable of providing informed consent and complying with all study procedures. At the end of the CCT phase (week 4), depression severity will be reassessed. To be eligible for Phase 2 (SSRI trial), participants will be required to have an HRSD score ≥ 14.
Exclusion
- Diagnosis of substance abuse or dependence (excluding Tobacco Use Disorder) within the past 12 months
- History of psychosis, psychotic disorder, mania, or bipolar disorder
- Primary neurological disorder, including dementia, stroke, Parkinson's disease, epilepsy, etc.
- Mini Mental Status Examination (MMSE) score less than 24
- HRSD suicide item greater than 2 or Clinical Global Impressions (CGI)-Severity score of 7 at baseline
- History of allergic or adverse reaction to escitalopram, or non-response to adequate trial of escitalopram (at least 4 weeks at dose of 20 mg) during the current episode
- Current or recent (within the past 2 weeks) treatment with psychotherapy, antidepressants, antipsychotics, mood stabilizers
- Contraindication to MRI scanning (such as metal in body) or inability to tolerate the scanning procedures
- History of significant radioactivity exposure (nuclear medicine studies or occupational exposure).
Key Trial Info
Start Date :
January 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04836533
Start Date
January 31 2023
End Date
January 31 2023
Last Update
March 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032